SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 695.46+2.0%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: CuttingEdge Bio who wrote (2771)10/29/2019 5:12:13 PM
From: Miljenko Zuanic   of 3557
 
<REGN was smart to go after the MRK leadership indications that dominate and will dominate the marketplace. By demonstrating similar-looking benefit in the same setting,...>

I doubt very much that third country international trial, even if similar in activity, will make bigger impact on US (part EU as well) market, and keytruda dominance? IF they want to compete v Keytruda, they should do US trial, cemiplimab v pembrolizumab. Period. Like they went after lucentis. But, I guess, their thirst for *advancement* is not that high as before (unfortunately).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News